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Abstract: Progression of HIV infection is variable among individuals, and definition disease
progression biomarkers is still needed. Here, we aimed to categorize the predictive potential
of several variables using feature selection methods and decision trees. A total of seventy-five
treatment-naïve subjects were enrolled during acute/early HIV infection. CD4+ T-cell counts (CD4TC)
and viral load (VL) levels were determined at enrollment and for one year. Immune activation,
HIV-specific immune response, Human Leukocyte Antigen (HLA) and C-C chemokine receptor
type 5 (CCR5) genotypes, and plasma levels of 39 cytokines were determined. Data were analyzed
by machine learning and non-parametric methods. Variable hierarchization was performed by
Weka correlation-based feature selection and J48 decision tree. Plasma interleukin (IL)-10, interferon
gamma-induced protein (IP)-10, soluble IL-2 receptor alpha (sIL-2Rα) and tumor necrosis factor
alpha (TNF-α) levels correlated directly with baseline VL, whereas IL-2, TNF-α, fibroblast growth
factor (FGF)-2 and macrophage inflammatory protein (MIP)-1β correlated directly with CD4+ T-cell
activation (p < 0.05). However, none of these cytokines had good predictive values to distinguish
“progressors” from “non-progressors”. Similarly, immune activation, HIV-specific immune responses
and HLA/CCR5 genotypes had low discrimination power. Baseline CD4TC was the most potent
discerning variable with a cut-off of 438 cells/µL (accuracy = 0.93, κ-Cohen = 0.85). Limited discerning
power of the other factors might be related to frequency, variability and/or sampling time. Future
studies based on decision trees to identify biomarkers of post-treatment control are warrantied.
Keywords: HIV; biomarkers; acute infection; disease progression; decision trees; soluble plasma
factors; HLA; immune responses
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1. Introduction
Human Immunodeficiency Virus (HIV) infection causes an irreversible deterioration of the
immune system ultimately leading to the development of AIDS in the vast majority of infected persons.
Following virus transmission, acute/early phase of infection is characterized by a high-level peak
of viremia, rapid loss of CD4+ T-cells in both peripheral blood and mucosal lymphoid tissues, and,
in some cases, clinical symptoms [1,2]. Emergence of HIV-specific CD8+ T-cell response is associated
with the drop of plasma viremia to a stable level; known as the viral set-point [3]. Within this general
framework, it is also known that the rate of disease progression after acquiring the infection is very
variable among individuals, allowing the identification of different subgroups: rapid progressors,
typical progressors, viremic controllers or elite controllers [4].
The application of biomarkers in the diagnosis and management of cardiovascular diseases,
several infections, immune and genetic disorders, as well as cancer is well known [5]. However, finding
a reliable biomarker able to predict the rate of disease progression after acute/early HIV infection
remains an important challenge. Nowadays, the HIV treatment guidelines recommended by the
United States, the World Health Organization, the International AIDS Society and the European AIDS
Clinical Society, adhere to providing universal combined antiretroviral treatment (cART) regardless
of the infected persons were undergoing recent or chronic infection [6–9]. This might diminish the
interest in finding a biomarker of disease progression. However, it should be considered that the
application of biomarkers is beyond disease prediction and monitoring. Identifying biomarkers helps
dissect the mechanisms underlying pathogenic processes and also plays an important role in drug
discovery/design, development and validation [10]. On the other hand, differential public health
approaches are necessary to maximize the use of constrained resources in low and middle-low income
countries. Finally, even though the guidelines state that therapy should be initiated soon after diagnosis,
they are not set in stone. Decisions must still be made on a case-by-case basis and the need to defer
cART because of the presence of clinical and/or psychosocial factors. Therefore, biomarkers may aid
in the medical decision for these particular cases. Thus, HIV biomarker is a field that still deserves
continuous research to fill in the gaps in different aspects of HIV pathogenesis, discover new targets,
improve current HIV treatment strategies, and aid in cure research.
Thus far, CD4+ T-cell counts and plasma viral load (VL) levels have remained the strongest
correlates of progression and are the two markers routinely used in the clinical setting to monitor the
infection [1]. In addition, other parameters such as levels of cell-associated viral DNA [11,12], immune
activation and inflammation [13,14], several cytokines [15–18], HIV-specific immune responses [19–25],
and genetic variants (recently reviewed in [26]) have been shown to be associated with disease
progression and proposed as potential biomarkers. However, different limitations preclude them from
being installed into the routine practice.
In 2008, an ongoing multicenter Argentine observational cohort of subjects diagnosed during
primary HIV infection, named Grupo Argentino de Seroconversión study group, was created in Argentina.
The aim of this consortium is to gather epidemiological, clinical, immunological and virological data
of the individuals enrolled to dissect variables associated with different rates of disease progression
soon after infection, and ultimately to identify potential markers associated with progression [27].
In an initial study based only on clinical variables, baseline VL > 100,000 copies/mL was associated
with progression [27]. Later, in this cohort, it was demonstrated that CD8+ T-cell specificity (higher
proportion of early anti-Group-specific antigen (Gag) T-cells), functionality (enhanced viral inhibitory
activity) and phenotype (preserved differentiation and lower proportion of exhausted cells) correlated
with delayed disease progression [28,29]. Moreover, disease progression, in terms of viral load,
could be correlated with a genetic score built based on Human Leukocyte Antigen (HLA) and C-C
chemokine receptor type 5 (CCR5) genotypes genotypes [30]. Finally, it could be demonstrated that
higher baseline T helper 17 (Th17) cell percentages were associated with lower baseline levels of
immune T-cell activation and to lower rates of disease progression [31].
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In this study, we took advantage of all these variables comprehensively studied in our cohort
and that have been individually associated with disease progression and aimed to categorize their
predictive potential. The complete set included 88 variables (16 clinical variables, 10 immunological
variables, 10 genetic variables and 52 variables related to soluble plasma factors) measured in up to 75
individuals. Due to the large number of variables analyzed, we first ranked sets of different variables
based on their correlations with each class of progression. Then, using the top ranked variables,
we studied their predictive power by constructing decision trees. This machine learning approach
generates a hierarchy of variables automatically and provides a quantitative measure of the predictive
capability of a given set. Moreover, the decision trees automatically provide the best cut-off values for
continuous variables and they are reliable classifiers.
2. Materials and Methods
2.1. Study Subjects
Seventy-five subjects with ongoing acute/early primary HIV infection (PHI) were enrolled by the
Grupo Argentino de Seroconversión study group [27], an ongoing multicenter Argentine observational
cohort of subjects diagnosed during primary HIV infection. Inclusion criteria for enrolment in the
cohort are: age >16 years at first evaluation, confirmed diagnosis of primary HIV infection, and first
(baseline) medical and laboratory evaluation (i.e., CD4 cell count and plasma HIV RNA) within six
months of the probable date of infection. Primary HIV infection is defined as: (1) detection of HIV
RNA or p24 antigen with a simultaneous negative or indeterminate Western blot assay; or (2) positive
Western blot with a negative diagnostic within the previous six months. Hence, it includes subjects
up to Fiebig VI. Data included in this study were obtained from enrolled subjects while they were
off-ART. Samples and data obtained after ART initiation were not considered in the analysis. Of note,
most subjects were enrolled between years 2008 and 2012, before international [32] and national [33]
treatment guidelines recommended that all HIV-infected subjects should initiate ART immediately
after diagnosis. Additionally, samples from 21 HIV-seronegative healthy donors (HD) were obtained
from voluntary blood donors at the Sanatorio Dr Julio Mendez blood bank (Buenos Aires, Argentina).
All donors were between 18 and 65 years old; completed and passed a survey on blood donation;
and were screened for serological markers of HIV, Hepatitis C virus, Hepatitis B virus, Human T- cell
lymphotropic virus I and II, Syphilis, Chagas disease, and Brucellosis before being accepted as donors.
2.2. Ethical Considerations
This study was reviewed and approved by two institutional review boards (IRB): Comité de
Ética Humana, Facultad de Medicina, Universidad de Buenos Aires (11/11/2010 ExpUBA35.366/2010
Res CD 2815/2010) and Comité de Bioética, Fundación Huésped (18/05/2009, Buenos Aires, Argentina).
Both HIV-infected participants and healthy donors provided written informed consents accepting to
participate in this study.
2.3. Samples
Blood samples were collected from study participants at enrollment (baseline sample) and at 6 and
12 months post-presumed date of infection. Whole blood was centrifuged to separate plasma and stored
at −80 ◦C until use. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll–Hypaque
density gradient centrifugation (GE Healthcare, Little Chalfont, UK) and cryopreserved for subsequent
functional assays.
2.4. HIV-1 Viral Load, CD4+ T-cell Count and Immune Activation
Plasma VL was determined by branched-DNA assay (bDNA, Versant HIV-1 RNA 3.0 assay,
Siemmens Healthcare, Erlangen, Germany). CD4+ T-cell count was determined by flow cytometry
double platform (BD FACSCanto, BD Biosciences, San Jose, CA, USA). CD4+ and CD8+ lymphocyte
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activation was analyzed on thawed and over-night rested PBMCs by flow cytometry. Cells were
stained for 30 min at 4 ◦C with LIVE/DEAD Fixable NEAR-IR (Life Technologies, Carlsbad, CA, USA)
to exclude dead cells, and with the following fluorochrome-conjugated antibodies (all of them from
BD Biosciences, San Jose, CA, USA): anti-HLA- antigen D Related (DR)- Fluorescein isothiocyanate
(FITC), anti-CD4-Peridinin Chlorophyll Protein Complex (PerCP), anti-CD38- Allophycocyanin (APC),
anti-CD3-Phycoerythrin-Cyanin7 (PeCy7) and anti-CD8-Phycoerythrin (PE). Cells were acquired
in a BD FACSCanto flow cytometer. Data acquisition and analysis was performed using the BD
FACSDiva v8.0.1 software (BD Biosciences, San Jose, CA, USA). Initial gating was performed on living
lymphocytes followed by gating on CD3+CD4+ or CD3+CD8+ events. Isotype-matched FITC- and
APC-conjugated non-specific antibodies were used in each sample to accurately set HLA-DR and
CD38 negative populations.
2.5. Human Leukocyte Antigen (HLA) and CCR5 Genotyping
HLA class I A and B typing was performed using an in-house protocol consisting in PCR
amplification, nucleotide sequencing with nested primers and web-based sequence interpretation.
CCR5-∆32 deletion was identified by differences in PCR product size. Single Nucleotide
Polymorphisms (SNPs) of the CCR5 gene corresponding to positions 29, 208, 627, 630, 676 and 927
were determined with Site Directed Mutagenesis-PCR-Restriction Fragment Length Polymorphism
(SDM-PCR-RFLP) assay. All procedures were previously described in Coloccini et al. [30].
2.6. HIV-Specific Cellular Immune Responses
The magnitude and specificity of the HIV-specific cellular immune response were screened by
interferon (IFN)-γ Enzyme-Linked ImmunoSpot Assay (ELISPOT) in baseline samples as described
previously [28,34].
2.7. Quantitation of Soluble Plasma Factors
Simultaneous determination of the following 39 cytokines and chemokines was performed using
Luminex technology (MILLIPLEX MAP Human Cytokine/Chemokine, Merck Millipore, Billerica,
MA, USA) in baseline samples: Endothelial growth factor (EGF), Eotaxin, fibroblast growth factor
(FGF)-2, Fms-like tyrosine kinase (Flt)-3 Ligand, Fractalkine, granulocyte colony-stimulating factor
(G-CSF), granulocyte-monocyte (GM)-CSF, GRO, IFN-α2, IFN-γ, interleukin (IL)-1α, IL-1β, IL-1rα,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, interferon
gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage
derived chemokine (MDC) (C-C motif chemokine (CCL)22), macrophage inflammatory protein
(MIP)-1α, MIP-1β, soluble CD40 ligand (sCD40L), soluble IL 2 receptor alpha (sIL-2Rα), tumor growth
factor (TGF)-α, tumor necrosis factor (TNF)-α, TNF-β, and vascular endothelial growth factor (VEGF).
Samples were processed and analyzed as described elsewhere [35]. Plasma lipopolysaccharide (LPS)
quantitation was performed using the Limulus Amebocyte Lysate (LAL) assay (QCL-1000, Lonza,
Walkersville, MD, USA).
2.8. Definitions and Data Analysis
The presumed date of infection was estimated as 14 days before the onset of symptoms or,
in asymptomatic subjects, as the midpoint between the last negative and the first positive test or one
month before the date of the indeterminate or negative Western blot assay [27]. Three dichotomic
classes were constructed to segregate subjects according to their rate of disease progression over the first
year postinfection or their capacity to control viral replication: C1 (defined on immunological criteria),
C2 and C3 (defined on virological criteria). In C1, subjects were segregated according to whether
their CD4+ T-cell count dropped below 350 cells/µL at any time during the first year postinfection
(“progressors”), or not (“non-progressors”) [27–29,31,36]. The 350 cells/µL-endpoint was chosen
based on the national and international recommendations for HAART initiation by the year 2010,
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when most of these individuals were already enrolled. C2 segregated subjects according to whether
they had >100,000 baseline HIV RNA copies/mL plasma or not, based on previous observations from
the same cohort [27]. Similarly, C3 segregated subjects according to whether they had >100,000 HIV
RNA copies/mL plasma or not at the 6-month sample (Figure 1A). The CD4 slope was calculated for
each subject as the slope of the best-fit line obtained by linear regression of CD4+ T-cell counts during
the first year of infection and was represented as the CD4+ T-cell count change per day (cells/µL/day).
Additive scores were created for each subject to compile host genetic information, as previously
described by our group [30]. Similarly, scores based on cytokine data were created. Construction of
genetic and cytokine-based scores is described in Appendix A, where all variables evaluated in this
study are defined. For certain analyses, the whole database was subdivided in three self-including
parts, i.e., the small database (N = 27), the intermediate database (N = 48) and the whole database
(N = 75) (Figure 1B).
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., La Jolla,
CA, USA) and IBM Corp. Released 2013, IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY:
IBM Corp. All data were analyzed using nonparametric statistics, unless otherwise stated. All p-values
were two-sided and considered to be statistically significant when p < 0.05. For correlations involving
plasma cytokine levels, p-values were adjusted for multiple comparisons using a false discovery rate
(FDR) procedure, according to the Benjamini and Hochberg method, with R Project software v. 3.4.1 (R
Foundation for Statistical Computing, Vienna, Austria). Adjusted p-values were considered significant
when less than 0.1. Finally, data was analyzed by machine learning methods. Variable hierarchization
was performed by Weka [37] (http://www.cs.waikato.ac.nz/ml/weka/v.3.7) using correlation-based
feature selection and J48 decision tree. Pictures of decision trees were made using KNIME Analytics
Platform (http://www.knime.comv3.4). Only trees with accuracy (of classification) and κ-Cohen [38]
values above 0.7 and 0.6, respectively, were reported as significant.
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Figure 1. (A) Definition of the three classes (C1, C2 and C3) used in this study to segregate subjects
into “progressors” and “non-progressors” or in relation to their ability to control viral replication.
These classes were used to construct decision trees. (B) The whole database was subdivided into three
self-including parts, i.e., the small database (N = 27), the intermediate base (N = 48) and the entire
base (N = 75). The dataset used in each analysis is indicated in the text. CD4+ and CD8+ T-cell counts
and viral load (VL) were determined in all subjects. Additionally, Human Leukocyte Antigen (HLA)
and C-C chemokine receptor type 5 (CCR5) genotyping (and the corresponding genetic scores (GS,
Appendix A)), HIV-specific immune responses and immune activation were determined in a subset of
48 subjects. Finally, 40 plasma soluble factors (39 cytokines and chemokines plus lipopolysaccharide
(LPS) were quantified in a smaller group (N = 27). The values obtained for each soluble factor were
used individually but also additive scores were constructed (CS, cytokine scores, Appendix A variables
plasma soluble factor (PSF)41 to PSF52). IA: Immune activation; IR: Immune response.
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3. Results
3.1. Cohort Description
A total of 75 recently-infected HIV positive (HIV+) subjects were enrolled. The summary of
subject´s characteristics is shown in Table 1. Eighty percent of enrolled subjects were identified on
the bases of presenting symptoms compatible to acute retroviral syndrome. Baseline samples were
obtained at a median of 75 days after the presumed date of infection. Most of the subjects were on Fiebig
V at enrollment. Medical and laboratory evaluation (CD4+ T-cell count and VL) were performed at
enrollment (baseline sample) and through one year. For the purposes of this study, data were recorded
as long as subjects remained off-ART. Thus, sample size dropped to N = 59 and N = 46 at 6 and 12
months postinfection, respectively. CD4+ and CD8+ T-cell counts and HIV+ plasma viral load were
determined longitudinally in the whole set of subjects (Table 1, Figure 2A,B). CD4+ T-cell count was
significantly lower at the 12-month sample compared to baseline (p = 0.001). Although CD4+ T-cell
counts were not determined in healthy donors (HD) enrolled for this study, unpublished data from
our group indicate that median CD4+ T-cell counts for a similar adult population from our country
(N = 118) is 834 cells/µL (IQR25–75% = 627–1080). This is significantly higher (Mann–Whitney test
p < 0.0001) compared to the baseline sample from the HIV+ subjects thus reflecting the early attrition of
the CD4+ T-cell subset which is characteristic of HIV infection. On the other hand, baseline VL was
significantly higher than 6-month and 12-month VLs (p < 0.0001 and p = 0.0026, respectively). However,
no difference was observed between 6-month and 12-month VLs, indicating that a set-point was already
established. Baseline immune activation was determined in a subset of 48 subjects. At the CD8+ T-cell
compartment, it was significantly higher than in healthy donors evidenced by higher percentages of
CD8+ T-cells expressing CD38 (p < 0.001) and CD38/HLA-DR (p = 0.0006) (Table 1, Figure 2C).
Table 1. Characteristics of HIV+ subjects enrolled in this study.
Total sample size (number of individuals) 75
Female:Male ratio 1:3
Age at enrollment (years, median and IQR25–75%) 30 (24–38)
Estimated time of infection at enrollment (days,
median and IQR25–75%) 75 (54–113)
Follow-up of Virologic and Immune Characteristics:
Baseline (N = 75) 6-month pi (N = 59) 12-month pi (N = 46)
VL (RNA copies/mL; median
and IQR25–75%) a 61,045 (12,736–455,417) 18,951 (4298–62,739) 16,988 (5695–40,105)
Log10VL (mean± SD) a 4.6 ± 1 4 ± 1 4 ±0.89
CD4+ T-cell count (cells/µL,
median and IQR25–75%) b 525 (361–698) 571 (406–673) 464 (387–585)
CD4/CD8 Ratio (Median and
IQR25–75%) 0.6 (0.32–0.83) 0.55 (0.34–0.8) 0.61 (0.39–0.93)
CD4+ T-cell decay rate
(cells/µL/day; median and
IQR25–75%)
−0.62 (−0.31 – −0.03)
Baseline Immune Activation (%cells, median and IQR25–75%) c:
%CD4+CD38+ 24.4 (16–36.2)
%CD4+HLA-DR+ 4.6 (1.5–11.01)
%CD4+CD38+HLA-DR+ 1.2 (0.47–2.8)
%CD8+CD38+ 45.2 (21.3–57.1)
%CD8+HLA-DR+ 26.5 (15.2–41)
%CD8+CD38+HLA-DR+ 13.8 (6.7–30.6)
a Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/mL,
respectively (1.7log10 and 5.7log10); b Flow cytometry double platform, FACSCanto, BD Biosciences; c Immune
activation was only evaluated at baseline samples by flow cytometry. IQR25–75: Interquartile range 25–75%.
VL: Viral Load. pi: postinfection. SD: Standard deviation. IQR: interquartile range; HLA-DR: Human leukocyte
antigen - antigen D Related.
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A total of 88 variables, including those described in the preceding paragraph were recorded in
enrolled subject (Appendix A). Due to technical limitations, some of these parameters were determined
in smaller cohort subsets (see Figure 1). Thus, plasma LPS, cytokines and chemokines were determined
in 27 subjects. These data were used to construct 12 cytokine-based scores (CS, Appendix A variables
PSF41 to PSF52). Similarly, immune activation, HLA and CCR5 genotypes, genetic scores (GS,
Appendix A variables G1 to G10) as well as magnitude and percentages of Nef- and Gag-specific
immune cells were determined in 48 subjects. Gender ratio and median age at enrollment were similar
across the three datasets.
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3.2. Association of Individual Parameters with Disease Progression 
We have previously described certain variables that, individually, were associated with disease 
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Figure 2. CD4+ T-cell counts, plasma viral load (VL), and immune activation of enrolled subjects.
All samples were obtained as long as the subjects remained treatment naïve. Longitudinal
determination of CD4+ T-cell counts (A); and plasma viral load (B) are shown (Baseline = enrollment
sa ple, 6 and 12 months postinfection). Dots represent data from individual subjects and lines
join matched values for each subject. Boxes represent the interquartile 25–75% range (IQR25–75)
and whiskers extend from 10th to 90th percentiles. Horizontal lines within boxes represent the
median. Immune activation (C) was evaluated at baseline as the percentage of CD38+, HLA-DR+
or CD38+/HLA-DR+ CD4+ (left panel) or CD8+ (right panel) T-cells. Dots represent data from
individual subjects. Median and IQR25-75 are shown in red. In A and B, p-values were calculated
using Wilcoxon test (baseline versus 6-month or 12-month samples). In C, p-values were calculated
using Kruskal–Wallis test followed by Dunn’s post-test to compare preselected pairs of datasets. PHI:
Primary HIV infection cohort. HD: Healthy donors. Asterisks denote p-values as follows: ** p < 0.01,
*** p < 0.005, **** p <0.0001.
3.2. Association of Individual Parameters with Disease Progression
We have previously described certain variables that, individually, were associated with disease
progression in this cohort. For the purpose of this study we chose to include the following variables in
this new analysis: immune activation because its level early after infection was associated with disease
progression [31] (variables IA1-IA6, see Appendix A), HIV-specific T-cell specificity because we have
shown that early Gag immunodominance was associated with slow rates of disease progression [28]
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(magnitude and percentages of Nef and Gag-specific T-cells; variables IR1-IR4), and genetic scores
built based on subject´s HLA and CCR5 genotypes because one score was previously associated with
lower baseline VL in this cohort [30] (variables G1–G8). These variables were chosen from the whole
set of variables that we investigated in this cohort, based on their strong association with disease
progression, and for their practicability to be measured in case it could be translated into the clinical
setting. In addition to this, cytokines, chemokines and LPS were evaluated in plasma from enrolled
subjects at baseline sample. Since the behavior of these variables in this cohort has not been described
previously, we first analyzed the expression of these factors in comparison to HD and its association
with markers of disease progression.
Out of the 39 cytokines and chemokines evaluated in plasma from enrolled subjects (N = 27),
six were significantly increased during PHI compared to HD: IL-1α, IL-10, IP-10, MIP-1α, sIL-2Rα,
and TNF-α. The highest increase was observed for sIL-2Rα which was seven-fold higher in PHI
compared to HD. This was followed by IL-1α, IL-10, MIP-1α, and IP-10 which were three times
elevated in PHI compared to HD, and TNF-α which was 1.7 times elevated in PHI. All but MIP-1α
remained significantly elevated after adjustment for multiple comparisons (FDR procedure). IL-15 was
significantly lower in PHI compared to HD (around 30% lower), even after FDR correction (Figure 3).
Then, we aimed to study interconnection of cytokines both in HD and in PHI, following the rational
proposed by Huang et al. [39]. For this, correlation analyses were performed among all cytokines
in both groups. In HD, 144 out of 647 correlations evaluated were statistically significant (22.7%)
while this ratio was 252/740 (34%) in PHI. Of those significant correlations, the r coefficients were
significantly higher in HD (median = 0.7335, IQR25–75 = 0.6755–0.8215) compared to PHI (median
= 0.4935 IQR25–75 = 0.435–0.555, p < 0.0001). Compared to HD, 68 significant correlations were
maintained in PHI, 71 significant correlations were lost, and 180 new significant correlations emerged.
This evidenced a rearrangement of the cytokine network during PHI, compared to HD.
Then, the relation of each cytokine and chemokine with CD4+ T-cell counts, plasma VL and
immune activation were determined. Baseline plasma levels of G-CSF and IP-10 inversely correlated
with baseline, 6-month and 12-month CD4+ T-cell percentages (%CD4+ T-cells). Similarly, baseline
plasma sIL-2Rα inversely correlated with baseline %CD4+ T-cells while baseline plasma IL-1α and
MCP-3 inversely correlated with 12-month %CD4+ T-cells. In the same line, baseline plasma IFNα2,
IL-8, MCP-1 directly correlated with CD4 slope (Figure 4). However, all these associations lost
statistical significance after FDR adjustment. On the other hand, baseline plasma IL-10, IP-10, TNF-α
and sIL-2Rα directly correlated with baseline VL and remained significant after adjustment (Figure 5).
However, no statistically significant association was found between cytokine and chemokine levels and
6-month or 12-month VL. Of note, subjects with over-limited baseline VLs (>500,000 RNA copies/mL)
were included in the analysis by setting the corresponding values at 500,000. The same analysis
was repeated excluding these values and all correlations remained statistically significant except
for IP-10. However, it should be noted that IP-10 is consistently found in the bibliography directly
associated with VL (See the discussion section). Thus, this lack of correlation is most likely the result
of reducing significantly the sample size (from 27 to 18) and the presence of one outlier. Finally,
correlations between these plasma molecules and baseline immune activation (defined as percentages
of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ T-cells) were studied. Baseline IL-2, TNF-α,
FGF-2 and MIP-1β directly correlated with percentages of activated CD4+ T-cells, while IL-2, TNF-α,
GM-CSF and GRO directly correlated with percentages of activated CD8+ T-cells (Figure 5). However,
only those correlations involving percentages of activated CD4+ T-cells remained significant after
FDR adjustment. In summary, a few cytokines and chemokines, most of them associated with a
pro-inflammatory profile except for IL-10, were elevated in PHI compared to HD. In contrast, IL-15 was
diminished. Some associations were found between baseline levels of these cytokines and CD4+ T-cell
count along time and also with CD4+ T-cell decay rate (CD4 slope). Though, these correlations lost
significance after correction, suggesting that they might not represent truly associations. Conversely,
correlations between IL-10, IP-10, TNF-α and sIL-2Rα and VL remained significant but they were
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only associated with baseline VL and not with 6-month and 12-month VL, which suggests that these
molecules may not have any predictive value over the course of infection but they would only be
related to the level of concurrent viral replication. No significant correlation was found between
baseline plasma LPS levels and CD4+ T-cell counts or plasma VL at any time-point.
Viruses 2018, 10, 34  9 of 24 
 
12‐month VL, which  suggests  that  these molecules may  not  have  any predictive  value  over  the 
course of  infection but  they would only be related  to  the  level of concurrent viral replication. No 
significant  correlation was  found between baseline plasma LPS  levels  and CD4+ T‐cell  counts or 
plasma VL at any time‐point. 
 
Figure 3. Plasma levels of IL‐1α, IL‐10, IL‐15, IP‐10, MIP‐1α, sIL‐2Rα, and TNF‐α in samples obtained 
at enrollment of recently  infected HIV+ subjects  (PHI, baseline samples) and healthy donors  (HD). 
Dots represent data from individual subjects. Median and interquartile ranges (IQR25–75) are shown 
in red. p‐values were calculated using Mann–Whitney test. Asterisks denote p‐values as follows: * p < 
0.05,  ** p < 0.01,  *** p < 0.005,  **** p < 0.0001. After  false discovery  rate  (FDR) adjustment, all but 
macrophage inflammatory protein (MIP)‐1α remained significantly different. 
Figure 3. Plasma levels of IL-1α, IL-10, IL-15, IP-10, MIP-1α, sIL-2Rα, and TNF-α in samples obtained
at enrollment of recently infected HIV+ subjects (PHI, baseline samples) and healthy donors (HD). Dots
represent data from individual subjects. Median and interquartile ranges (IQR25–75) are shown in red.
p-values were calculated using Mann–Whitney test. Asterisks denote p-values as follows: * p < 0.05,
** p < 0.01, *** p < 0.005, **** p < 0.0001. After false discovery rate (FDR) adjustment, all but macrophage
inflammatory protein (MIP)-1α remained significantly different.
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Figure 4. (A) Correlations between plasma level of denoted cytokines and chemokines (evaluated at 
baseline samples) versus percentages of CD4+ T-cells evaluated at the denoted time-points. (B) 
Correlations between the plasma level of denoted cytokines and chemokines (evaluated at baseline 
samples) versus daily CD4+ T-cell count decay rate (CD4 slope, cells/μL/day). Dots represent data 
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Figure 4. (A) Correlations between plasma level of denoted cytokines and chemokines (evaluated
at baseline samples) versus percentages of CD4+ T-cells evaluated at the denoted time-points.
(B) Correlations between the plasma level of denoted cytokines and chemokines (evaluated at baseline
samples) versus daily CD4+ T-cell count decay rate (CD4 slope, cells/µL/day). Dots represent data
from individual subjects. In the inset, r (upper line) and p (lower line) values correspond to Spearman’s
test. After correction for multiple comparisons (FDR procedure) was applied, none of these correlations
remained statistically significant.
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3.3. Baseline CD4+ T-cell Count Was the Most Potent Variable to Distinguish “Progressors” from
“Non-Progressors”
Then, we aimed to weight the association of each variable ith disease progression. For this
purpose, three individual discrete dichotomic classes were constructed to segregate subjects according
the criteria described in Materials and Methods section, and as shown in Figure 1A. In addition,
for these analyses the whole database was subdivided into three self-including parts, i.e., the small
database (N = 27), the intermediate database (N = 48) and the whole database (N = 75) (see Methods
and Figure 1B). First, correlations between C1, C2 and C3 with all other individual variables as well
as cytokine-based and genetic scores were studied using Weka correlation based feature selection
along the three databases (Figure 6A). Strong correlations (r > 0.6) were mainly found with clinical
parameters: baseline CD4+ T-cell counts, baseline CD4+ T-cell percentages and baseline CD4/CD8
ratios strongly correlated with C1 (r = 0.8321, 0.7495 and 0.6493, respectively). The r values correspond
to correlations studied based on the small database (N = 27), although they remained above 0.6
when repeating the analyses with the intermediate database (0.7944, 0.6901 and 0.6535, respectively).
However, only baseline CD4+ T-cell counts and baseline CD4+ T-cell percentages strongly correlated
with class C1 when using the largest dataset (0.7210 and 0.62983, respectively). CST4 (Appendix A)
and baseline CD4+ T-cell counts strongly correlated with C2 (r = 0.62307 and 0.6130, respectively) in
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the small database. However, the magnitude of the latter association was lost when using the bigger
database. Surprisingly, no strong correlation was found when studying C3 in all the analyses.
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Figure 6. (A) Variable hierarchization using correlation based feature selection between classes C1
and C2 with all other individual variables as well as cytokine-based (CS) and genetic scores (GS),
along with the three databases (small (N = 27), medium (N = 48), and large (N = 75)). Only strong
correlations (>0.6) are shown. No correlation was found between the variables studied and C3. Decision
trees were constructed to discriminate “progressors” from “non-progressors” as defined by: C3 (B);
and C1 (C). To build the tree shown in (B), the clinical variables were not included in the analysis.
(D) Baseline CD4+ T-cell counts of the individuals enrolled segregated as “progressors” (yes, red
dots) and “non-progressors” (no, black dots) according to C1. The cut-off value as defined by the
tree shown in C is depicted by the vertical dashed line. CST4: cytokine score CST4 (see Appendix A).
GS8: genetic score 8 (see Appendix A). The number of instances considered in D and C was the result
of the elimination of cases with missing class value.
Then, with the aim of detecting the most predictive variables for infection progression, J48 decision
trees were constructed using different sets of variables on the three self-including databases. Thus,
for each database, trees were automatically generated using the whole set of variables (including
genetic and cytokine-based scores), the intermediate subset of variables (all variables excluding the
clinical dataset) and a small set of variables comprising only the cytokine-related variables. By using
this methodology, none of the cytokine-related or immune (immune activation or immune responses)
variables had good predictive value to distinguish between the groups of subjects segregated according
to C1, C2 or C3. Only GS8 (Appendix A) could discriminate “high 6-month VL” from “low 6-month
VL” as defined by C3 with good power (accuracy = 0.905, κ-Cohen = 0.767, Figure 6B), provided
the clinical variables were not included in the analysis. The resulting tree had only one branch
that split the feature GS8 with a cut-off value=59.21: most of the “6-month VL below 105” subjects
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were separated into the ≤59.21 branch while most of the “6-month VL above 105” subjects were
separated into the >59.21 branch. When the clinical parameters were included in the dataset to
build the trees, these variables always outcompeted all other variables including the cytokine and
genetic scores, i.e., immune activation, HIV-specific immune responses, HLA haplotypes and soluble
factors had lower discrimination power when compared to clinical parameters. Always, the clinical
parameters were included in the analysis, and baseline CD4+ T-cell count was the most potent variable
to distinguish “progressors” from “non-progressors” defined by C1 with a cut-off of 438 cells/µL
in the N = 75 database (accuracy = 0.929, κ-Cohen = 0.853; Figure 6C,D). Here, most “progressors”
and no “non-progressors” were separated into the ≤438 branch. The >438 branch contained 15%
“progressors” and 85% “non-progressors” that could be separated into a subsequent branch by the
baseline percentage of CD4+ T-cells.
4. Discussion
Progression of HIV infection is variable among individuals and the definition of disease
progression biomarkers is still fundamental. Apart from CD4+ T-cell count and VL, several parameters
individually showed associations with the rate of disease progression, as shown by our group and
others [11–31]. Here, we took advantage of results found in our well characterized cohort of acute/early
HIV infected subjects from Argentina. This cohort was fully enrolled in our country, and the vast
majority of the subjects enrolled are native, which distinguishes this cohort from others from Africa,
Europe and Asia. The analysis included a rich dataset of 16 clinical variables, six immune activation
variables, four cellular immune response variables, 10 genetic variables and 52 variables related to
plasma soluble factors. The behavior of some of these variables in this cohort, in particular their
individual associations with disease progression, has been described elsewhere [27–31]. The aim of the
study was to categorize their predictive potential using decision trees and to analyze their possible
implementation in the clinical setting.
The so-called “cytokine storm” occurring during the first weeks after HIV infection is a
well-known phenomenon [18,39–41]. In line with this, plasma levels of IL-1α, IL-10, IP-10, sIL-2Rα,
and TNF-α were significantly elevated (from 1.7 to 7 times) in the baseline samples from subjects
enrolled in the cohort, compared to HD. The elevation of IL-1α, IP-10, sIL-2Rα, TNF-α may be
indicating the activation of a pro-inflammatory response, not only to HIV-encoded pathogen-associated
molecular patterns (PAMPs) but also to bacterial PAMPs exposed as a result of the gut-associated
lymphoid tissue early disruption [1,42]. IL-10 elevation might be the result of an attempt to control
the pro-inflammatory burst [18,43]. In addition, it depicts the activation of innate immunity effectors
and also T-cells. On the other hand, a modest albeit significant reduction in IL-15 was observed.
This cytokine play key roles in both innate and adaptive responses by participating in the expansion and
differentiation of Natural Killer (NK) cells and also by contributing to the homeostasis of the memory
T cell pool. Several reports indicated that IL-15 was elevated during HIV acute infection [18,40,44,45]
while others reported no changes [15,16]. These discrepancies could be attributed to the fact that IL-15
peaks very fast after infection and then sharply decays [39,41,44]. Thus, sampling time after infection
can significantly affect the results. Apart from the mere increment in the plasma concentration
of cytokines, a more intricate relationship between all cytokines was observed in acute infection,
compared to HD, evidenced by the rearrangement of correlations among the cytokines studied. This is
in line with a recent report indicating that HIV imposes a new order on the cytokine network, which in
turn could contribute to disease [39].
Correlation analysis between plasma cytokines in baseline samples revealed several associations
with clinical parameters such as CD4+ T-cell count, viral load and immune activation either evaluated in
the same or in subsequent samples. All correlations involving CD4+ T-cell count (including CD4 slope)
and CD8+ T-cell activation lost significance after adjustment for multiple comparison. Conversely, IL-2,
TNF-α, FGF-2 and MIP-1β remained significantly correlated with concurrent CD4+ T-cell activation.
Noel et al. have reported that plasma levels of IP-10, sCD163, IL-6 and MCP1 directly correlated
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both with CD4+ and CD8+ T-cell activation (measured as percentage of CD38+HLA-DR+ cells) in a
cohort of chronically-infected HIV controllers [46]. More relevant to our context, Liovat et al. reported
that levels of IP-10, IL-18 and TGF-β1, measured early after infection, correlated with CD8+ T-cell
activation measured at six months postinfection, but CD4+ T-cell activation was not evaluated [16].
The fact that associations (and the strength of those associations) between individual cytokines and
immune activation differed whether the evaluation was performed in the CD4+ or the CD8+ T-cell
compartment provides support to the notion that different forces (for instance, immune homeostasis
or viral replication itself), could be driving cellular activation in each compartment [43]. Above all,
the strongest correlations were those found between baseline levels of IL-10, IP-10, TNF-α and sIL-2Rα
with baseline VL. Of note, these cytokines did not correlate with subsequent VL values suggesting
that they might have no predictive value over VL course, at least in this cohort. Instead, these
associations might be reflecting that the magnitude of the “cytokine storm” is directly or indirectly
influenced by the magnitude of concurrent viral replication as suggested by others [15,18,39]. Of note,
these cytokines belong to divergent families and, with the exception of sIL2Rα, they have also been
associated previously with the magnitude of HIV replication during acute infection [15,16]. TNF-α
is a potent effector of the antiviral immunity and also can increase viral replication by enhancing
proviral transcription. Suppressor activity of IL-10 might help control immune-mediated damage
during infection and also limits HIV-specific response favoring viral persistence. IP-10 (or C-X-C motif
chemokine (CXCL)-10) is a chemokine induced by IFN-γ, which has been consistently found to be
elevated in different stages of HIV infection, including acute/early infection, and it has been mostly
associated with the worst-case scenarios in terms of disease progression [15,39,46–51]. In particular,
two studies [16,52] identified IP-10 level during acute infection as a predictor of rapid disease
progression. Although in this work baseline IP-10 correlated with concurrent VL, it failed to predict
subsequent VL or discriminate progressors from non-progressors, as in the publications mentioned.
Finding an early marker of disease progression is not a new concept but it has been proven to
be a very difficult task. For instance, Roberts et al. [15] have developed a model to predict the VL
set point and also a risk score of progression, both based on measuring a panel of plasma cytokines
early after infection. Those equations in our cohort were tested but the outcome was unsuccessful
in terms of progression prediction. The cohort used by Roberts et al. included exclusively African
women, and showed a high prevalence of sexually transmitted infections other than HIV. On the
contrary, our cohort comprises Caucasian men mainly. This, together with other limitations of our
study, which are mentioned below, could explain the negative results when trying to apply their
model in our cohort. Beyond that, it does nothing but emphasize the difficulties when trying to find a
universal marker of HIV disease progression. In the same line, Mahnke et al. [12] postulated immune
activation (measured as %CD38+CD8+ T-cells), cell-associated VL (CAVL) and CD8+ T-cell phenotype
(%CCR5+CD8+ T-cells) as early predictors of disease progression. While CAVL and %CCR5+CD8+
T-cells were not measured in this study, %CD38+CD8+ T-cells showed no potential as predictive factors.
As in our study, HIV-specific CD8+ T-cell response has also been evaluated by Mahnke et al. as a
possible predictor of disease progression and, in consonance with our findings, it only proved to be a
weak predictor of progression over other factors.
Discordant results between this and previous studies could be explained by differences in the
premises used to define disease progression, in the methodologies used to analyze the data and the time
in which the baseline samples were obtained (in relation to infection date). In particular, one limitation
of this study might be the wide variation in the timing of baseline sample collection and that most
samples were obtained during the late acute/early infection. However, this could also be interpreted
as a better reflection of the real life, since the already unusual detection of an acutely infected subject
in clinics, most usually happens at Fiebig stage IV–VI. Thus, the results obtained using this kind of
more “real” cohorts would be easier to translate into the real practice. Above all, the discrepancies and
the difficulty in finding a reliable acute infection marker of disease progression most likely reflect the
diversity and the extreme dynamics of the events that follow HIV infection.
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Here, after analyzing 88 variables in a well-defined cohort of seroconverters and where disease
progression (within the first year postinfection) was defined by several means, baseline CD4+ T-cell
count emerged as the only variable able to predict rapid progression by machine learning methods.
Many correlations between variables have been studied and several significant values were obtained.
However, strong correlations do not necessarily imply predictive power over disease progression.
Based on this, a two-way analysis was used: first correlations were used for filtering variables and
then their predictive power was analyzed using the J48 algorithm which generates the decision trees.
In an attempt to identify potential co-biomarkers of progression that may go along with CD4+ T-cell
count, all possibilities of analysis were exhausted, i.e., including and excluding sets of data one by
one. However, these efforts were unsuccessful. Interestingly, when CD4+ T-cell count was the only
variable removed from the analysis, baseline VL appeared as the next variable with power to discern
“progressors” from “non-progressors”. No other variables (neither immune nor genetic) have been able
to displace the classical parameters used to date to monitor disease progression. Thus, our approach
reaffirms the predictive power of CD4+ T-cell count (and the lack of power of the other variables)
despite the scarce available data. Interestingly, the CD4+ T-cell count complies with most requirements
needed to be a good biomarker [5]: its assessment is objective and precise with current methodologies,
it is reliable, it is directly related to the disease mechanism, and, as particularly shown in this work,
it is able to identify early events in the natural history of the disease. Importantly, rapid, reliable,
and affordable point-of-care CD4 tests are being developed. This will allow its rapid determination
not only in centralized institutions but also in peripheral areas which will, in turn, rapidly aid in
decision making and intervention [53]. In addition, this result highlights the importance of CD4+
T-cell count for monitoring HIV infection even when there is an increasing trend to minimize its use at
least in virally suppressed subjects [54,55]. Noteworthy, a significant proportion of subjects (19 out
of 75, 25%) had low CD4+ T-cell counts (<350 cells/µL) already at baseline sample, as observed also
in other cohorts [56]. This emphasizes the need for interventions aimed at detecting acutely-infected
subjects and at linking them to care immediately. On the other end, high baseline CD4+ T-cell counts
(>500 cells/µL) were observed even in subjects that progressed rapidly after infection. This provides
further support to comply with current treatment guidelines, which suggest early ART initiation.
Overall, our machine learning approach to tackling this problem was based on feature selection
and decision trees. Feature selection allowed us to reduce the large number of available variables
to significant ones in terms of correlation with the class. On the other hand, decision tree algorithm
provides appropriate classifiers to work with scarce data and with readable outputs in a simple way.
Thus, the use of feature selection and decision trees proved to be a valid methodology to weight
putative biomarkers of disease progression following HIV infection. In the era of HIV cure strategies
research, studies aimed at identifying biomarkers of post-treatment control are being encouraged.
For instance, it is being increasingly clear that the VL magnitude reached during acute/early infection
directly correlates with the reservoir size after cART is started [57,58]. In the same line, persistently
high levels of pro-inflammatory cytokines after ART initiation might indicate low-level ongoing viral
replication in anatomically privileged sites [59]. Altogether, elevated cytokines early after infection
could impact both the seeding and the maintenance of the viral reservoir. Thus, it is tempting to
hypothesize that the cytokines that were elevated during PHI in our cohort and particularly those that
associated with higher baseline VL would serve as biomarkers of reservoir size after cART initiation.
This would be an instrumental tool in the context of cure strategies. Thus, subsequent studies in this
field using feature selection and decision trees are warrantied.
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Appendix
Table A1. List and description of variables evaluated in this study. In addition to individual variables,
scores were constructed to compile host genetic (variables G1 to G10) and plasma soluble factor (PSF41
to PSF52) data for each subject.
Variable ID Variable Name Variable Description
C1 Baseline CD4 Absolute CD4+ T-cell count evaluated at enrollment
C2 Baseline %CD4 Percentage of CD4+ T-cells evaluated at enrollment
C3 Baseline CD4/CD8 CD4/CD8 ratio evaluated at enrollment
C4 6mo CD4 Absolute CD4+ T-cell count evaluated at 6 months postinfection
C5 6mo %CD4 Percentage of CD4+ T-cells evaluated at 6 months postinfection
C6 6mo CD4/CD8 CD4/CD8 ratio evaluated at 6 months postinfection
C7 12mo CD4 Absolute CD4+ T-cell count evaluated at 12 months postinfection
C8 12mo %CD4 Percentage of CD4+ T-cells evaluated at 12 months postinfection
C9 12mo CD4/CD8 CD4/CD8 ratio evaluated at 12 months postinfection
C10 CD4 Slope Rate of CD4
+ T-cell decay over the first year postinfection
(cells/µL/day)
C11 Baseline VL Plasma viral load evaluated at enrollment (RNA copies/mL)
C12 Baseline log10VL Log10 plasma viral load evaluated at enrollment
C13 6mo VL Plasma viral load evaluated at 6 months postinfection (RNAcopies/mL)
C14 6mo log10VL Log10 plasma viral load evaluated at 6 months postinfection
C15 12mo VL Plasma viral load evaluated at 12 months postinfection (RNAcopies/mL)
C16 12mo log10VL Log10 plasma viral load evaluated at 12 months postinfection
IA1 CD4CD38 Percentage of CD4+ CD38+ T-cells evaluated at enrollment
IA2 CD4HLADR Percentage of CD4+ HLA-DR+ T-cells evaluated at enrollment
IA3 CD4double Percentage of CD4
+ CD38+ HLA-DR+ T-cells evaluated at
enrollment
IA4 CD8CD38 Percentage of CD8+ CD38+ T-cells evaluated at enrollment
IA5 CD8HLADR Percentage of CD8+ HLA-DR+ T-cells evaluated at enrollment
IA6 CD8double Percentage of CD8
+ CD38+ HLA-DR+ T-cells evaluated at
enrollment
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Variable ID Variable Name Variable Description
IR1 %Nef response Percentage of T-cell response directed to Nef (over totalHIV-specific response) evaluated at enrollment by ELISPOT
IR2 Absolute Nefresponse
Magnitude of Nef-specific response evaluated at enrollment by
ELISPOT (SFU/million PBMC)
IR3 %Gag response Percentage of T-cell response directed to Gag (over totalHIV-specific response) evaluated at enrollment by ELISPOT
IR4 Absolute Gagresponse
Magnitude of Gag-specific response evaluated at enrollment by
ELISPOT (SFU/million PBMC)
G1 GS1
Additive genetic score constructed based on the presence or
absence of certain HLA alleles, as described previously [30].
Alleles with a previous reported protective effect were added (+1),
and risk alleles were subtracted (-1). Based on relevant
bibliography, HLA-A*02, HLA-A*32, HLA-A*68, HLA-B*15,
HLA-B*13, HLA-B*27, HLA-B*32, HLA-B*39, HLA-B*44,
HLA-B*51 and HLA-B*57 were considered as protective.
HLA-A*11, HLA-A*23, HLA-A*24, HLA-B*08, HLA-B*35,
HLA-B*53, HLA-C*04 and HLA-C*07 were considered as
deleterious. Other HLA alleles were considered as neutral (0).
Heterozygosis for HLA was considered as protective (1) and
homozygosis as deleterious (–1).
G2 GS3
Additive genetic score constructed based on the presence or
absence of certain HLA alleles and CCR5 genotypes, as described
previously [30]. HLA alleles associated with protection or risk
were considered as in GS1. For CCR5 polymorphisms, ∆32 and
CCR2-64I alleles were considered as protective. CCR5 genotypes
HHC/HHF*2 and HHC/HHG*2 were considered as protective
(+1), HHC/HHE, HHE/HHE and HHE/HHG*2 were considered
as deleterious (–1), and the others as neutral (0).
G3 GS5
Additive genetic score constructed based on adding +1 when a
protective allele was present and subtracting −1 when a risk allele
was present. Protective and risk alleles were determined based on
the odd ratio obtained for each allele in our cohort with a p < 0.05.
HLA alleles with p > 0.05 were considered as neutral (0).
G4 GS6 Idem to GS5 but the cut-off level for significance was establishedat p < 0.03.
G5 GS7
Constructed by multiplying the odds ratio corresponding to the
6-month CD4+ T-cell count for each of the 6 HLA alleles (A, B and
C) of each individual.
G6 GS8
Constructed by multiplying the odds ratio corresponding to the
6-month VL for each of the 6 HLA alleles (A, B and C) of each
individual.
G7 GS9
Constructed by multiplying the odds ratio corresponding to the
6-month CD4+ T-cell count for each of the 2 CCR5 haplotypes of
each individual.
G8 GS10 Constructed by multiplying the odds ratio corresponding to the6-month VL for each of the 2 CCR5 haplotypes of each individual.
G9 GS11
Constructed by multiplying the odds ratio corresponding to the
6-month CD4+ T-cell count for each of the 6 HLA alleles (A, B and
C) and the 2 CCR5 haplotypes of each individual.
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Variable ID Variable Name Variable Description
G10 GS12
Constructed by multiplying the odds ratio corresponding to the
6-month VL for each of the 6 HLA alleles (A, B and C) and the 2
CCR5 haplotypes of each individual.
PSF1 EGF Plasma level of EGF (Endothelial growth factor) evaluated atenrollment by Luminex (pg/mL)
PSF2 Eotaxin Plasma level of Eotaxin evaluated at enrollment by Luminex(pg/mL)
PSF3 FGF2 Plasma level of FGF-2 (fibroblast growth factor 2) evaluated atenrollment by Luminex (pg/mL)
PSF4 Flt3Ligand Plasma level of Flt-3 (Fms-like tyrosine kinase 3) ligand evaluatedat enrollment by Luminex (pg/mL)
PSF5 Fractalkine Plasma level of Fractalkine evaluated at enrollment by Luminex(pg/mL)
PSF6 GCSF Plasma level of G-CSF (granulocyte colony-stimulating factor)evaluated at enrollment by Luminex (pg/mL)
PSF7 GMCSF
Plasma level of GM-CSF (granulocyte monocyte
colony-stimulating factor) evaluated at enrollment by Luminex
(pg/mL)
PSF8 GRO Plasma level of GRO evaluated at enrollment by Luminex(pg/mL)
PSF9 IFN-α2 Plasma level of IFN-α2 (interferon alpha 2) evaluated atenrollment by Luminex (pg/mL)
PSF10 IFN-γ Plasma level of IFN-γ (interferon gamma) evaluated at enrollmentby Luminex (pg/mL)
PSF11 IL1α Plasma level of IL-1α (interleukin 1 alpha) evaluated atenrollment by Luminex (pg/mL)
PSF12 IL1β Plasma level of IL-1β (interleukin 1 beta) evaluated at enrollmentby Luminex (pg/mL)
PSF13 IL1ra Plasma level of IL-1ra (interleukin 1 receptor antagonist)evaluated at enrollment by Luminex (pg/mL)
PSF14 IL2 Plasma level of IL-2 (interleukin 2) evaluated at enrollment byLuminex (pg/mL)
PSF15 IL3 Plasma level of IL-3 (interleukin 3) evaluated at enrollment byLuminex (pg/mL)
PSF16 IL4 Plasma level of IL-4 (interleukin 4) evaluated at enrollment byLuminex (pg/mL)
PSF17 IL5 Plasma level of IL-5 (interleukin 5) evaluated at enrollment byLuminex (pg/mL)
PSF18 IL6 Plasma level of IL-6 (interleukin 6) evaluated at enrollment byLuminex (pg/mL)
PSF19 IL7 Plasma level of IL-7 (interleukin 7) evaluated at enrollment byLuminex (pg/mL)
PSF20 IL8 Plasma level of IL-8 (interleukin 8) evaluated at enrollment byLuminex (pg/mL)
PSF21 IL9 Plasma level of IL-9 (interleukin 9) evaluated at enrollment byLuminex (pg/mL)
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Variable ID Variable Name Variable Description
PSF22 IL10 Plasma level of IL-10 (interleukin 10) evaluated at enrollment byLuminex (pg/mL)
PSF23 IL12p40 Plasma level of IL-12p40 (interleukin 12 subunit p40) evaluated atenrollment by Luminex (pg/mL)
PSF24 IL12p70 Plasma level of IL-12p70 (interleukin 12) evaluated at enrollmentby Luminex (pg/mL)
PSF25 IL13 Plasma level of IL-13 (interleukin 13) evaluated at enrollment byLuminex (pg/mL)
PSF26 IL15 Plasma level of IL-15 (interleukin 15) evaluated at enrollment byLuminex (pg/mL)
PSF27 IL17 Plasma level of IL-17 (interleukin 17) evaluated at enrollment byLuminex (pg/mL)
PSF28 IP10 Plasma level of IP10 (interferon gamma-induced protein 10,CXCL10) evaluated at enrollment by Luminex (pg/mL)
PSF29 MCP1 Plasma level of MCP1 (monocyte chemoattractant protein 1)evaluated at enrollment by Luminex (pg/mL)
PSF30 MCP3 Plasma level of MCP3 (monocyte chemoattractant protein 3)evaluated at enrollment by Luminex (pg/mL)
PSF31 MDC Plasma level of MDC (macrophage derived chemokine, CCL22)evaluated at enrollment by Luminex (pg/mL)
PSF32 MIP1α Plasma level of MIP-1α (macrophage inflammatory protein 1alpha) evaluated at enrollment by Luminex (pg/mL)
PSF33 MIP1β Plasma level of MIP-1β (macrophage inflammatory protein 1 beta)evaluated at enrollment by Luminex (pg/mL)
PSF34 sCD40L Plasma level of sCD40L (soluble CD40 ligand) evaluated atenrollment by Luminex (pg/mL)
PSF35 sIL2Rα Plasma level of sIL-2Rα (soluble interleukin 2 receptor alpha)evaluated at enrollment by Luminex (pg/mL)
PSF36 TGFα Plasma level of TGF-α (tumor growth factor alpha) evaluated atenrollment by Luminex (pg/mL)
PSF37 TNFα Plasma level of TNF-α (tumor necrosis factor alpha) evaluated atenrollment by Luminex (pg/mL)
PSF38 TNFβ Plasma level of TNF-β (tumor necrosis factor beta) evaluated atenrollment by Luminex (pg/mL)
PSF39 VEGF Plasma level of VEGF (vascular endothelial growth factor)evaluated at enrollment by Luminex (pg/mL)
PSF40 LPS Plasma level of LPS (lipopolysaccharide) evaluated at enrollmentby Lal assay (EU/mL)
PSF41 CSVL1
Cytokines that significantly correlated with baseline VL were
considered (sIL-2Rα, TNF-α, IP-10 and IL-10) to construct an
additive score based on 1s and −1s. If the cytokine value of the
subject was above 75% IQR corresponding to the group of healthy
donors (HD), then this cytokine was assigned a value of 1. If the
value was below 25% IQR corresponding to HD, it was assigned a
value of −1. If the value was within the range IQR25–75%
corresponding to HD, it was assigned a value of 0.
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PSF42 CSCD41
Cytokines that significantly correlated with baseline CD4+ T-cell
counts were considered (sIL-2Rα, IP-10 and G-CSF) to construct
an additive score based on 1s and −1s. If the cytokine value of the
subject was above 75% IQR corresponding to the group of healthy
donors (HD), then this cytokine was assigned a value of −1. If the
value was below 25% IQR corresponding to HD, it was assigned a
value of 1. If the value was within the range IQR25–75%
corresponding to HD, it was assigned a value of 0.
PSF43 CST1 Score defined as the arithmetic sum of CSVL1 + CSCD41.
PSF44 CSVL2
Cytokines that significantly correlated with baseline VL were
considered (sIL-2Rα, TNF-α, IP-10 and IL-10) to construct an
additive score based on adding the corresponding Spearman’s R
values. If the cytokine value of the subject was above 75% IQR
corresponding to the group of healthy donors (HD), then the
Spearman´s R value corresponding to that cytokine was added to
the score. If the value was below 25% IQR corresponding to HD,
the Spearman´s R value corresponding to that cytokine was
subtracted from the score. If the value was within the range
IQR25–75% corresponding to HD, it was assigned a value of 0.
PSF45 CSCD42
Cytokines that significantly correlated with baseline CD4+ T-cell
counts were considered (sIL-2Rα, IP-10 and G-CSF) to construct
an additive score based on adding the corresponding Spearman’s
R values. If the cytokine value of the subject was above 75% IQR
corresponding to the group of healthy donors (HD), then the
Spearman´s R value corresponding to that cytokine was
subtracted from the score. If the value was below 25% IQR
corresponding to HD, the Spearman´s R value corresponding to
that cytokine was added to the score. If the value was within the
range IQR25–75% corresponding to HD, it was assigned a value of
0.
PSF46 CST2 Score defined as the arithmetic sum of CSVL2 + CSCD42
PSF47 CSVL3
Cytokines that significantly correlated with baseline VL were
considered (sIL-2Rα, TNF-α, IP-10 and IL-10) to construct an
additive score based on normalizing the value of each of these
cytokines over the cytokine median of the PHI group and
multiplying this adjusted value by the corresponding Spearman´s
R.
PSF48 CSCD43
Cytokines that significantly correlated with baseline CD4+ T-cell
counts were considered (sIL-2Rα, IP-10 and G-CSF) to construct
an additive score based on normalizing the value of each of these
cytokines over the cytokine median of the PHI group and
multiplying this adjusted value by the corresponding Spearman´s
R.
PSF49 CST3 Score defined as the arithmetic sum of CSVL3 + CSCD43.
PSF50 CSVL4
Cytokines that significantly correlated with baseline VL were
considered (sIL-2Rα, TNF-α, IP-10 and IL-10) to construct an
additive score based on multiplying the log10 value of each of
these cytokines by the corresponding Spearman´s R.
PSF51 CSCD44
Cytokines that significantly correlated with baseline CD4+ T-cell
counts were considered (sIL-2Rα, IP-10 and G-CSF) to construct
an additive score based on normalizing the log10 value of each of
these cytokines by the corresponding Spearman´s R
PSF52 CST4 It was defined as the arithmetic sum of CSVL4 + CSCD44
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